Comparative Pharmacology
Head-to-head clinical analysis: LIPOFEN versus TRILIPIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPOFEN versus TRILIPIX.
LIPOFEN vs TRILIPIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lipofen (fenofibrate) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It activates PPARα, which increases lipolysis and elimination of triglyceride-rich particles from plasma by stimulating lipoprotein lipase activity and reducing apolipoprotein C-III production. This leads to decreased triglyceride levels and increased HDL cholesterol.
TRILIPIX (fenofibric acid) is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase, and reduces production of apoprotein C-III.
For hypertriglyceridemia: 67-134 mg (as fenofibric acid) orally three times daily with meals. Maximum dose 200 mg/day.
135 mg orally once daily, not to exceed 135 mg/day.
None Documented
None Documented
5-7 hours (prolonged in renal impairment; may exceed 24 hours in severe CKD).
Terminal elimination half-life of fenofibric acid is approximately 20 hours (range 10-35 hours), allowing once-daily dosing.
Primarily renal (90% as unchanged drug), with <5% fecal.
Primarily renal excretion as glucuronide conjugate and unchanged drug; ~60% of dose excreted in urine as fenofibric acid and its glucuronide, ~25% in feces.
Category C
Category C
Fibrate Antilipemic
Fibrate Antilipemic